Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel

Trial Profile

Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 19 Feb 2018 Status changed from suspended to recruiting.
    • 18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, between 6/2016 and 2/2017, 20 patients were enrolled.
    • 18 Oct 2017 Results (n=20) assessing combination pembrolizumab and low dose weekly carboplatin\paclitaxel for patients with recurrent\metastatic nsclc and performance status of 2, were presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top